Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-642-7 | CAS number: 144-83-2
Additional toxicological data
Administrative data
- Endpoint:
- additional toxicological information
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 1943
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Cases on the Thoracic Surgical Unit at Harefield
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 943
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- GLP compliance:
- no
Test material
- Reference substance name:
- SULPHAPYRIDINE
- IUPAC Name:
- SULPHAPYRIDINE
- Test material form:
- solid: particulate/powder
- Remarks:
- migrated information: powder
- Details on test material:
- No data
Constituent 1
Results and discussion
Any other information on results incl. tables
Up to 10 g. of sulphapyridine powder placed in the pleural cavity at operation has, in 22 cases, barely and infrequently led to therapeutic levels of the drug in the blood. The maximum level reached was 5.5 mg. per 100 c.cm. This compared with maxima of 10 mg. per 100 c.cm. often reached after the intraperitoneal administration of sulphanilamide. The average time for complete excretion of sulphapyridine had been found to be six days, while other workers had found that sulphanilamide was completely excreted in four days when placed intraperitoneally. Absorption of sulphapyridine through the pleura was irregular from case to case, greatly differing amounts of drug being found in both the pleural fluid and the blood at the same times after operation. This was probably due to caking of the powdered drug and the formation of pleural adhesions which interfere with free absorption.
Applicant's summary and conclusion
- Conclusions:
- Absorption of sulphapyridine through the pleura was irregular from case to case, greatly differing amounts of drug being found in both the pleural fluid and the blood at the same times after operation. This was probably due to caking of the powdered drug and the formation of pleural adhesions which interfere with free absorption.
- Executive summary:
Up to 10 g of sulphapyridine powder was administrated in the pleural cavity at operation in 22 cases during 6 days. During the time, the amount of the sulphapyridine was determinded in the blood and pleural fluid.
The maximum level reached was 5.5 mg. per 100 c.cm. This compared with maxima of 10 mg. per 100 c.cm. often reached after the intraperitoneal administration of sulphanilamide. The average time for complete excretion of sulphapyridine had been found to be six days, while other workers had found that sulphanilamide was completely excreted in four days when placed intraperitoneally.
Absorption of sulphapyridine through the pleura was irregular from case to case, greatly differing amounts of drug being found in both the pleural fluid and the blood at the same times after operation. This was probably due to caking of the powdered drug and the formation of pleural adhesions which interfere with free absorption.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
